Imunomoduliuojančio issetines sklerozšs gydymo efektyvumo vertinimo galimybes: surišantieji, neutralizuojantieji antikunai ir MxA baltymo indukcija.

Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system that is the major course of the disability of young adults. The relapsing-remitting multiple sclerosis can be treated with immunomodulatory drugs - interferon-beta (IFN-β) and glatiramer acetate. One of the major clinical problems with the interferon-beta is the development of binding (BAB's) and neutralizing antibodies (NAB's). It is probable that the presence of Nabs, especially in persistently high titers, is associated with a reduction in the radiographic and clinical effectiveness of IFN-β treatment. We review the features of the development of NAB's, the factors influencing the development, clinical importance of NAB's and EFNS, and AAN guidelines regarding the assessment of their clinical and radiographic impact. We describe the results of our pivotal trial that studies the binding antibodies against IFN-β and their clinical impact. [ABSTRACT FROM AUTHOR]